Introduction {#S0001}
============

Cancer remains the major cause of death globally. In 2018, approximately 18 million new cases and 9 million deaths from cancer were estimated to occur worldwide.[@CIT0001] Several chemotherapeutic agents have been developed for treatment and prevention of cancer, either chemically synthetic drugs or herb-derived compounds.[@CIT0002]--[@CIT0006] As herb-derived anticancer drugs are considered to be less toxic compared with synthetic drugs, attentions to developing new drugs originating from herbal products have substantially been paid worldwide. These include leelamine, the natural active compound from the bark of pine tree,[@CIT0007] atractylodin and β-eudesmol, the natural active compounds from rhizomes of *Atractylodes lancea* (Thunb) DC,[@CIT0008] and alantolactone, an active sesquiterpene from *Inula helenium* L.[@CIT0009]

Drug metabolism and pharmacokinetic (DMPK) studies play an important role in all steps of drug discovery and development, including anticancer drugs.[@CIT0010] Metabolism is the process of which xenobiotics or endogenous substances in the body are biotransformed to the metabolic products that facilitate their elimination.[@CIT0011] Drug metabolism involves two main phases, i.e., phase I and phase II metabolism. The primary enzyme system involved in phase I metabolism is cytochrome P450 (CYP), and the major enzymes involved in phase II are UDP-glucuronosyltransferase (UGT), sulfotransferase (SULT), glutathione-S-transferase (GST), *N*-acetyltransferase (NAT), and methyltransferase (MT).[@CIT0012] Drug metabolism plays a crucial role in determining the efficiency and safety of drugs. Drugs undergo metabolism to form numerous stable metabolites, most of which are pharmacologically inactive. On the other hand, in some cases, metabolism may lead to reactive metabolites that can induce adverse effects. Various types of drug metabolism studies have been incorporated during the process of drug discovery and development to generate new chemical entities (NCE) with acceptable safety profiles. This is particularly important for cancer chemotherapeutic drugs with a narrow therapeutic window. Metabolite profiling and identification studies of these compounds and currently used drugs are therefore essential. The main aim of metabolic profiling studies is to identify metabolic pathways and metabolites generated from the biotransformation process. The information obtained from the studies would help to optimize lead compounds for optimal pharmacokinetic and pharmacodynamic properties. Besides, it will help to identify new chemical entities based on the metabolites generated to minimize potential safety liabilities due to the formation of reactive or toxic metabolites. Comparison of information obtained from preclinical studies in animals and humans would also ensure potential adequate coverage of human metabolites in animals and for supporting human prediction.

This systematic review aimed to summarize the research articles relating to the metabolite profiling studies of anticancer drugs (conventional chemical synthetic drugs and targeted small-molecules) and candidate compounds from herbal sources. Factors influencing metabolite profiles (metabolic pathways and types of metabolites generated) and their relationship with anticancer activity and toxicity in vitro, in vivo (animals), and human were also investigated.

Materials and Methods {#S0002}
=====================

Study Selection and Inclusion and Exclusion Criteria {#S0002-S2001}
----------------------------------------------------

This systematic review was performed through the search from PubMed (via Endnote) and ScienceDirect databases up to January 2019. The following keywords were used: "anticancer drug", "anticancer agent", "chemotherapy", "chemotherapeutic drug", "traditional medicine", herbal medicine, "natural compound", "metabolism", "metabolite profile", "metabolite identification", "metabolite characterization", and "cancer". No other search conditions were applied. All articles obtained from the two databases were checked for duplication. The remaining articles were initially screened as per the inclusion criteria based on the content of the abstract section. The inclusion criteria for article selection were 1) articles in full-texts and written in English; 2) articles with the investigation (in vitro, in vivo, or clinical studies) of metabolite profiles of conventional chemotherapeutic drugs, small molecules targeted therapy, candidate synthetic anticancer agents, natural products-derived anticancer compounds or drug candidates. The duplicates, review articles, short communications, case reports, articles with the investigation of other types of drug metabolism studies, or those with insufficient information of metabolite(s) or metabolic pathway(s) were excluded from data analysis.

Data Extraction and Collection {#S0002-S2002}
------------------------------

Two independent researchers performed data extraction from all articles. When conflicting opinions arose, the decision was sought from higher professional level personnel, and the decision was considered final. The title and abstract of each article search from PubMed (via Endnote) and ScienceDirect databases using the keywords mentioned above were initially screened for relevant original articles based on the inclusion and exclusion criteria. The full-text articles were carefully examined to confirm their compliance with the defined eligibility criteria. The studies of metabolite profile of chemotherapeutic drugs, targeted small molecules, candidate synthesized anticancer agents, traditional or herbal medicines, and natural compounds for cancer were classify according to types of anticancer agents. The information extracted included: name of anticancer drug or compound/herb, type of studies (in vitro, in vivo, and clinical studies), gender and species of animals used, route and dose of administration of the investigated drugs/compounds, biochemical tools used (liver, prostate, intestine, or kidney microsomes, subcellular fractions, hepatocytes, recombinant enzymes, and whole blood), type of biological samples (plasma, urine, bile, feces, and tumor), and study conclusion.

Results {#S0003}
=======

Study Description {#S0003-S2001}
-----------------

Three hundred and twenty-one out of 830 articles were duplicated or review articles and were initially excluded from the analysis. The title and abstract were further screened based on eligible criteria, and 411 articles were further excluded from the analysis. Finally, 78 out of 98 articles were included in the analysis; 20 excluded articles were case reports, short communications, and articles with insufficient information. The flow diagram of the search process is presented in [Figure 1](#F0001){ref-type="fig"}. Information on metabolite profiles including biochemical tools/biological samples used in the studies of conventional anticancer drugs, synthetic anticancer candidates, small molecules targeted therapy, herb-derived compounds with anticancer activities are summarized in [Tables 1](#T0001){ref-type="table"}--[3](#T0003){ref-type="table"}, respectively and the anticancer activities of each compound are presented in [Table 4](#T0004){ref-type="table"}.Table 1Metabolism Studies (Metabolite Profiling) of Conventional Synthetic Anticancer DrugsAnticancer DrugType of StudyBiochemical Tool/Animal/Human (Route: Dose)Type of SampleAnalytical TechniqueOutcomeRef.MetaboliteMetabolic PathwayEfficacy/Toxicity of MetaboliteAM6−36 (3-amino-6-(3′-aminopropyl)-5H-indeno\[1,2-c\]isoquinoline-5,11-(6H)dione)In vitroHLM, human hepatocyte--HPLC-QTOF-MS, HPLC-QqQ-MS1 Metabolite for HLM (4);\
7 Metabolites for hepatocyte (4--10)Reduction (4);\
Monoacetylation (5);\
Conversion of amino acid group to an alcohol (7);\
Reduction of the ketone to an alcohol +conversion of amino acid group to an alcohol (8);\
Reduction + acetylation (6);\
Monoacetylation + conversion of amino acid group to an alcohol (9);\
Glucuronidation (10)Metabolites 5: lower retinoid X receptor (RXR) homodimers bind to DNA response elements (RXRE) induction activity than parent compound AM6-36\
Metabolites 8: exhibited lower activity to inhibit NFƘB than AM6-36\[[@CIT0013]\]In vivoFemale Sprague−Dawley rats (PO: 40 mg/kg)Serum, liver, mammary tissues1 Metabolites for serum (5);\
5 Metabolites for liver tissue (4, 5, and 7--9);\
No metabolite in mammary tissueARQ 501 (synthetic β-lapachone)In vitroMouse, rat, dog, monkey, human whole blood--UPLC-QTOF-MS,\
HPLC-MS-ARC4 Metabolites for mouse and rat (M1, M2, M3, M5);\
5 Metabolites for dog (M1, M2, M3, M5, unidentified metabolite);\
5 Metabolites for monkey (M1, M2, M3, M5, M6);\
6 Metabolites for human (M1, M2, M3, M4, M5, M6);\
ARQ 501 disappeared after 60 min of incubation in human whole bloodOxidation (M1);\
Adding 2 oxygen and 2 hydrogen atoms (M2);\
Adding 1 oxygen and 2 hydrogen atoms (M3);\
Loss of 1 carbon atom (M4 and M6);\
Loss of CO group (M5)Not evaluated\[[@CIT0014]\]ARQ 501 (synthetic β-lapachone)In vivoMice (IP: 40 mg/kg), rats (IV: 40 mg/kg)PlasmaLC-QTOF-MS, HPLC-QqQ-MS3 Metabolites for all speciesGlucosylation + sulfation;\
Glucuronidation;\
SulfationNot evaluated\[[@CIT0015]\]Clinical trialCancer patients (140 mg/m^2^)3 MetabolitesCabazitaxelPhase I clinical trialAdvanced solid tumor patients (IV: 25 mg/m^2^ of \[^14^C\]-cabazitaxel (50 muCi, 1.85 MBq of \[^14^C\]-cabazitaxel))Plasma, urine, fecesHPLC-RD-MS6 Metabolites in plasma (Major: RPR123142);\
10 Metabolites in urine (Major: M09b);\
13 Metabolites in feces (Major: RPR104943, RPR104952, RPR111026, RPR111059)7-*O*-demethylation + 10-*O*-demethylation + hydroxylation (RPR104952);\
10-*O*-demethylation (RPR123142);\
7-*O*-demethylation + 10-*O*-demethylation + di-hydroxylation (M09b);\
7-*O*-demethylation + di-hydroxylation + 10-*O*-demethylation (RPR111026, RPR111059);\
7-*O*-demethylation + di-hydroxylation + 10-*O*-demethylation + hydroxylation (RPR104943);\
Cleavage is minor pathway plasma and urineNot evaluated\[[@CIT0016]\]CapecitabineIn vivoMale Wistar rats (PO: 80 mg/kg)Bile, urine, liver, kidneysHPLC-TIS-MS/MS, ^19^F-NMR and ^1^H-NMR3 Metabolites for liver (5ʹ-deoxy-5-fluorocytidine, α-Fluoro-β-alanine, 2ʹ-(β-D-glucuronic acid)-5ʹ-deoxy-5-fluorocytidine);\
2 Metabolites for bile (5ʹ-deoxy-5-fluorocytidine, 2ʹ-(β-D-glucuronic acid)--5ʹ-deoxy-5-fluorocytidine);\
2 Metabolites for kidney (5ʹ-deoxy-5-fluorocytidine, α-Fluoro-β-alanine);\
4 Metabolites for urine (5ʹ-deoxy-5-fluorouridine, 5.6-Dihydro-5-fluorouracil, α-Fluoro-β-alanine, 5ʹ-deoxy-5-fluorocytidine)Glucuronidation (2ʹ-(β-D-glucuronic acid)-5ʹ-deoxy-5-fluorocytidine);\
Not identified (5ʹ-deoxy-5-fluorocytidine, α-fluoro-β-alanine, 5ʹ-deoxy-5-fluorouridine, 5.6-Dihydro-5-fluorouracil)Not evaluated\[[@CIT0017]\]Carbendazim (2-benzimidazolecarbamic acid methyl ester)In vitroRLM, HLM--HPLC-ESI-MS1 Metabolite (5(6)- or 4(7)-hydroxyl carbendazim)OxidationNot evaluated\[[@CIT0018]\]In vivoRats (PO: 1000 mg/kg)Serum1 Metabolite (2-aminobenzimidazole)HydrolysisCI941 (losoxantrone)In vitroRat hepatocyte, human hepatoblastoma (HepG2) cell lines--HPLC-UV, HPLC-QqQ-MS, ^1^H-NMR12 Metabolites (M2-M13) for rat hepatocyte;\
No metabolite in HepG2Hydroxylation (M2, M3);\
Hydroxylation + oxidation (M8);\
Hydroxylation + oxidation + glutathione conjugation (M10);\
Hydroxylation+ glucuronidation (M4, M9);\
Hydroxylation + sulfation (M5-M7);\
Oxidation (M11-M13)Not evaluated\[[@CIT0019]\]CisplatinIn vivoMale Sprague-Dawley rats (IV: 3mg/kg)Kidney tissueHPLC-ESI-QTOF-MS31 Metabolites (M1-M31)Hydration (M1);\
Hydroxylation (M4);\
Dihydroxylation (M3);\
Methionine conjugation (M5);\
Di-methionine conjugation (M15, M29);\
Cysteine conjugation (M7, M8);\
Di-cysteine conjugation (M16, M31);\
Chlorination (M24, M26);\
Acetylcysteine conjugation (M9, M10);\
Di-acetylcysteine conjugation (M17);\
Glutathione conjugation (M11);\
Thioether conjugation (M13);\
Hydration+ hydroxylation (M2);\
Methionine conjugation + hydroxylation (M6);\
Methionine conjugation + chelation (M18, M20, M25);\
Methionine conjugation + chelation + hydroxylation (M19);\
Cysteine conjugation+ chelation (M21, M23, M27, M28, M30);\
Cysteine conjugation+ chelation + hydroxylation (M22);\
Glutathione conjugation +hydroxylation (M12);\
Thioether conjugation + hydroxylation (M14)Not evaluated\[[@CIT0020]\]CP-31398 (N'-\[2-\[2-(4-methoxyphenyl)ethenyl)-4-quinazolinyl\]-N,N-dimethyl-1,3-propanediamine\
dihydrochloride)In vivoMale and Female CD rats (PO: 0, 240, 480, or 960 mg/m^2^/day) and beagle dogs (0, 200, 400, or 800 mg/m^2^/day)PlasmaHPLC-QTOF-MS4 Metabolites for rat (II: hydroxy CP-31398, III: *O*-demethyl CP-31398, IV: *N*-demethyl CP-31398, V: hydroxy *O*-demethyl CP-31398);\
4 Metabolites for dog (II: hydroxy CP-31398, III: *O*-demethyl CP-31398, IV: *N*-demethyl CP-31398, VI: di-demethyl CP-31398)Hydroxylation (hydroxy CP-31398);\
*O*-demethylation (*O*-demethyl CP-31398);\
*N*-demethylation (*N*-demethyl CP-31398);\
Hydroxylation + *O*-demethylation (hydroxy *O*-demethyl CP-31398);\
Di-demethylation (di-demethyl CP-31398)Not evaluated\[[@CIT0021]\]CPA (Cyproterone acetate)In vivoFemale Wistar-Han rats (PO: 50 mg/kg \[^3^H\] CPA (0.42 MBq/mg))BileHPLC-MS, GC-MS, ^1^H-NMR2 Metabolites (M1: 3α-OH-CPA and M2)Sulfation and/or Glucuronidation3α-OH-CPA covalently bound to guanine which might be the major adduct formed of CPA\[[@CIT0022]\]CrisnatolIn vitroHuman hepatoma (Hep G2) cells, HLM--GC-MS, ^1^H-NMR3 Metabolites for Hep G2 (M1 and M2: isomeric crisnatol dihydrodiol and M3: crisnatol 1,2-dihydrodiol);\
2 Metabolites for HLM (M4: crisnatol 1,2-dihydrodiol and M5: 1-hydroxycrisnatol)Di-hydroxylation + di-hydrogenation (M3, M4);\
Hydroxylation (M5)Not evaluated\[[@CIT0023]\]CyclophosphamideClinical trialCancer patients (60 mg/kg)Plasma, urineGC-MS1 Active metabolite for both samples (N, N-bis(2-chloroethyl) phosphorodiamidic acid)Not identifiedNot evaluated\[[@CIT0024]\]DFS (Trans-2,6-difluoro-4ʹ-(*N, N*)-dimethylamino) stilbene: Stilbene analog)In vitroPooled MLM, RLM, HLM--HPLC-ESI-MS/MS10 Metabolites for MLM (M1-10);\
7 Metabolites for RLM (M1, M3-6, M9-10);\
6 Metabolites for HLM (M1-3, M5, M7, M10)Demethylation (M1);\
Oxidation (M2-M4);\
Demethylation + Oxidation (M5);\
Oxidation + Defluorination (M6, M7);\
Bisoxidation (M8, M9);\
Isomerization (M10)Not evaluated\[[@CIT0025]\]5ʹ-dFUR (5ʹ-deoxy-5-fluorouridine)In vivoCancer patients (IV: 4 g/m^2^)PlasmaGC-MS3 Metabolites (*N*^3^-Methylated-5ʹ-dFUR, 5-fluorouracil, and 5,6-dihydro-5-fluorouracil)Methylation (*N*^3^-Methylated-5ʹ-dFUR);\
Not identified (5-fluorouracil, and 5,6-dihydro-5-fluorouracil)Not evaluated\[[@CIT0027]\]5ʹ-dFUrd (5ʹ-deoxy-5-fluorouridine)Clinical trialCancer patients (IV: 10 g/m^2^)Blood, plasma, urine^19^F-NMR4 Metabolites in blood and plasma (5-fluorouracil, α-fluoro-β-ureidopropionic acid, α-fluoro-β-alanine, 5,6-dihydrofluorouracil);\
3 Metabolites in urine (5-fluorouracil, α-fluoro-β-ureidopropionic acid, α-fiuoro-β-alanine)Not identifiedNot evaluated\[[@CIT0026]\]EAPB0203In vitroPooled RLM, DLM--HPLC-MS/MS (QqQ and QTOF),\
^1^H-NMR, ^13^C-NMR4 Metabolites for DLM (EAPB0202, M7, M2, and M1);\
6 Metabolites for RLM (EAPB0202, M7, M6, M3, M2, M1)Hydroxylation (M1-M3, M6, M7);\
Demethylation (EAPB0202)Not evaluated\[[@CIT0028]\]EAPB0503 (imiquimod analogs) and EAPB0502 (M' 7) and EAPB0603 (M'5) (active metabolites of EAPB0503)In vitroMLM, RLM, DLM, HLM;\
Rat, dog, and human hepatocyte--LC-ESI-MS/MSEAPB0503:\
6 Metabolites for MLM (M'2-M'7);\
4 Metabolites for RLM (M'2, M'4, M'5, M'7);\
7 Metabolites for DLM (M'1-M'7);\
4 Metabolites for HLM (M'2, M'4, M'5, M'7);\
4 Metabolites for rat hepatocyte (M'2, M'4, M'5, and M'7);\
5 Metabolites for dog hepatocyte (M'1, M'2, M'4, M'6, M'7);\
4 Metabolites for human hepatocyte (M'2, M'4, M'5, M'7)\
EAPB0502:\
2 Metabolites for MLM (M'2 and M'3);\
2 Metabolites for RLM (M'2 and M'3);\
2 Metabolites for DLM (M'2 and M'3);\
1 Metabolite for HLM (M'2);\
1 Metabolite for rat hepatocyte (M'3)\
EAPB0603:\
2 Metabolites for MLM (M'1, M'2);\
1 Metabolite for RLM (M'2);\
2 Metabolites for DLM (M'1, M'2);\
1 Metabolite for HLM (M'2);\
1 Metabolite for dog hepatocyte (M'1)*O*-demethylation (M'5);\
*N*-demethylation (M'7); Hydroxylation (M'4, M'6);\
*O*- and *N*-demethylation (M'2);\
*N*-demethylation + hydroxylation (M'3);\
Hydroxylation + *O*-demethylation (M'1)Not evaluated\[[@CIT0029]\]E-DE-BPH (E-3,4-bis (4-Ethylphenyl) hex-3-ene: stilbene derivatives)In vitroRLM (Aroclor 1254-treated), PLM--HPLC-UV, GC-MS, GC-IR5 Metabolites for Aroclor 1254-treated RLM (M1: 3,4-bis(4-(1-hydroxyethyl) phenyl) hex-3-ene, M2: E-3-(4-acetylphenyl)-4-(4-(1-hydroxyethyl) phenyl) hex-3-ene, M3: E-3,4-bis(4-acetylphenyl) hex-3-ene, M4: E-3-(4-(1-hydroxyethyl) phenyl)-4-(4-ethylphenyl) hex-3-ene, M5: E-3-(4-acetylphenyl)-4- (4-ethylphenyl) hex-3-ene);\
4 Metabolites for PLM (M1, M2, M4, M5)Hydroxylation (M4);\
Hydroxylation + oxidation (M5);\
Di-hydroxylation (M1);\
Hydroxylation + oxidation + hydroxylation or di-hydroxylation + oxidation (M2);\
Hydroxylation + oxidation + hydroxylation + oxidation or di-hydroxylation + di-oxidation (M3)Not evaluated\[[@CIT0030]\]2-F-araA (9-β-D-arabinofuranosyl-2-fluoroadenine)In vivoMale BDF~1~ mice (IV: 400 mg/m^2^), female beagle dog (IV: 400 mg/m^2^), female rhesus monkey (IV: 400 mg/m^2^)Urine, bloodHPLC-MS1 Metabolite detected in dog blood (9-β-D-arabinofuranosyl hypoxanthine: 2-F-araH);\
2 Metabolites for urine of all species (2-fluoroadenine: 2-F-ad, 2-F-araH)Not identified2-F-araH: no antitumor activity, no toxicity in BDF~1~ mice bearing L1210 leukemia cells at 200 mg/kg (IP) for 9 days\[[@CIT0031]\]FlutamideIn vitroMale human, male dog, and male rat liver microsomes\
Male pig liver and prostate microsomes--LC-ESI-QTOF-MSLiver microsomes:\
1 Metabolites for human (OH-Flu);\
4 Metabolites for dog (Flu-1, OH-Flu (2 isoforms), M1, M3);\
4 Metabolites for rat (Flu-1, OH-Flu (3 isoforms), M1, M3 (2 isoforms));\
4 Metabolites for pig (Flu-1, OH-Flu (2 isoforms), M1, M3)\
Prostate microsomes:\
2 Metabolites for pig (OH-Flu, Flu-5)Monohydroxylation (OH-Flu);\
Di-hydroxylation (M1);\
Tri-hydroxylation (M3);\
Sulfation (Flu-3 sulfate);\
Glucuronidation (Flu-3 glucuronide);\
Hydroxylation + mercapturic acid conjugation (hydroxyflutamide mercapturic acid);\
Hydroxylation + glucuronidation (hydroxyflutamide glucuronide); Di-hydroxylation + glucuronidation (M1 glucuronide)Formation of a mercapturic acid conjugate from flutamide in human urine, suggesting that the\
reported liver effects of flutamide are due to the molecular mechanism\
caused by a reactive intermediate\[[@CIT0032]\]In vivoProstate cancer patients) (Oral: 250 mg BID)Urine10 Metabolites (Flu-1, Flu-3, Flu-3 sulfate, Flu-3 glucuronide, OH-Flu, M1, M3, hydroxyflutamide mercapturic acid, hydroxyflutamide glucuronide, M1 glucuronide)4-HydroxyanisoleIn vivoMalignant melanoma patients (IA: 80 g)UrineGC-MS4 Metabolites (1: hydroquinone, 3: 3.4-dihydroxyanisole, 4: 3-methoxy-4-hydroxyanisol, and 5: 4-hydroxy-3-methoxyanisole)Methylated metabolites might be conjugated with glucuronic acid or sulphatesNot evaluated\[[@CIT0033]\]IrinotecanIn vitroHLM, recombinant CYP enzymes (1A1, 1A2, 2C8, 2C9, 3A4, 3A5, and 3A7)--HPLC-Spectro-fluorometry, HPLC-MS4 Metabolites for cells expressing CYP3A4 (M1, NPC, M2, APC);\
5 Metabolites for microsomes containing CYP3A4 and CYP3A5 (M1, NPC, M2, APC, M4);\
1 Metabolite for cells expressing CYP3A5 (M4);\
No metabolite for cells expressing CYP2C8, CYP2C9, CYP1A1, CYP1A2, and CYP3A7Mono-hydroxylation (M1, M2);\
Loss of terminal piperidine (NPC);\
Di-oxidation (APC);\
De-ethylation (M4)Not evaluated\[[@CIT0034]\]Phase I and II clinical trialsCavum carcinoma patient (IV: 300 mg/m^2^), brain tumor patient (600 mg/m^2^), glioblastoma patients (350 mg/m^2^)Urine7 Metabolites (SN-38-G, M1, NPC, M2, M3, APC, SN-38)IxabepiloneClinical trialCancer patients (IV: 70 mg; 80 nCi)Plasma, urine, fecesHPLC-AMS, LC-MS3 Degradants and 4 metabolites for plasma and urine (Deg-1--Deg-3, M8, M16, M19, M41);\
3 Degradants and 3 metabolites for feces (Deg-1--Deg-3, M8, M19, M41)Dehydration (Deg-1-Deg-3);\
Dehydration + oxygenation (M41);\
Hydroxylation (M8);\
Oxygenation + dehydrogenation (M16);\
Oxygenation + dehydration (M19)Not evaluated\[[@CIT0035]\]JM216 (bis (acetato) ammine-dichloro (cyclohexylamine)\
Platinum (IV))Phase I clinical trialCancer patients (PO: 120, 200, 300, 420, 540 mg/m^2^)PlasmaHPLC-MS6 Platinum metabolites (A, JM383, JM559, D, JM118, F)Hydrolysis + declorination (JM518, JM559);\
Di-hydrolysis + di-declorination (JM383);\
Hydrolysis + declorination +reduction + clorination (JM118);\
Hydrolysis + declorination + reduction + glutathione conjugation + methylation (A)JM118: higher cytotoxic activity against 8 human ovarian carcinoma cell lines (HX 62, SKOV-3, CH1, CH1 CISR, 41M, 41M CISR, A2780 A2780 CISR) compared to JM216 and cisplatin\
JM518 and JM383: similar and less cytotoxic activity to JM216\[[@CIT0036]\]In vitroHuman plasmaPlasma5 Platinum metabolites (A, JM383, JM559, JM518, JM118)K02 (Morpholine-urea-Phe-Hphe-vinylsulfone)In vitroHLM, cDNA-expressed CYP3A4--HPLC-UV, LC-MS3 Major metabolites for both (M12, M19, M20)HydroxylationNot evaluated\[[@CIT0037]\]LaromustineIn vitroRLM, DLM, HLM, MLM--HPLC-RD7 Similar metabolites for all species but in different quantity (C1-C7: C4 = major metabolite)Demethylsufoxidation.;\
Hydrolysis;\
OxidationNot evaluated\[[@CIT0038]\]2-MethoxyestradiolIn vitroPooled HLM--HPLC, HPLC-QqQ -MS4 Phase I metabolites (A, B, C, D);\
2 Phase II metabolites (G1, G2)Hydroxylation (A, B, C, D);\
Glucuronidation (G1, G2)Not evaluated\[[@CIT0039]\]In vivoCancer patients (PO: 800 mg or 2200 mg BID)Urine2 Phase II metabolites (G1, G2)Glucuronidation (G1, G2)Mitomycin CIn vivoMurine adenocarcinomas of the colon, MAC 16 (high DT-diaphorase activity) and\
MAC 26 (low DT-diaphorase activity) bearing mice (Intra tumor: 500 µg)TumorHPLC-UV4 Metabolites (*trans*-hydro, *cis*-hydro, 2,7-diaminomitosene (2,7-DM), decarbamoyl 2,7-DM)Hydrolysis (*trans*-hydro, *cis*-hydro);\
Reduction (2,7-DM);\
Reduction + decarbamoyl (decarbamoyl 2,7-DM)Not evaluated\[[@CIT0040]\]NB-506 (6-*N*-formylamino-12,13-dihydro-1,11-dihydroxy-13-(b-D-glucopyranosil) 5*H*-indolo \[2,3-*a*\] pyrrolo \[3,4-*c*\] carbazole-5,7(6*H*)-dione)In vivoMale Sprague-Dawley rat (IV: 187.5 mg/m^2^ of \[^14^C\] NB-506 (1.85 MBq/kg))BileHPLC-RD-MS, ^1^H NMR, ^13^C NMR3 Metabolites (RBM-1, RBM-2, ED501)Deformyl metabolite (ED501);\
*O*-glucuronidation (RBM-1);\
ED501 + glucuronidation (RBM-2)Not evaluated\[[@CIT0041]\]9NC (9-nitro-20(*S*)-camptothecin)In vivoWistar rats (IV: 8 mg/kg)Bile, urine, fecesLC-IT-MS, LC-QTOF-MS (M2, M5 and M7), ^1^H NMR5 Metabolites for bile (M1, M2, M3: 9-AC, M4: 9-AA-CPT, M5);\
3 Metabolites for urine (M1, M3, M6);\
3 Metabolites for feces (M4, M6, M7: 9-OH-CPT)Glucuronidation of 9-OH-CPT (M1);\
Loss of glutamic acid from M5 (M2);\
Reduction (M3);\
Acetylation (M4);\
Glutathione conjugate of 10-OH-CPT (M5);\
Mercapturic acid conjugate of 10-OH-CPT (M6);\
Aglycone of M1 (M7)Not evaluated\[[@CIT0042]\]NSC 141549 (4ʹ-(9-Acridinylamino) methanesulfon-m-a nisidide *(m* -AMSA))In vivoMale Sprague-Dawley rats (IV: 60 mg/kg and IP: 40 mg/kg)Plasma (IV), bile (IP)HPLC-MS1 Major metabolite for plasma (4-amino-3-methoxymethanesulfonanilide);\
1 Major metabolite for bile (9-acridinyl thioether of glutathione)Methoxylation (4-amino-3-methoxy methanesulfonanilide);\
Glutathione conjugation (9-acridinyl thioether of glutathione)Not evaluated\[[@CIT0043]\]NSC 652287 (2,5-bis(5-hydroxymethyl-2-thienyl) furan)In vitroDog liver S9 fraction--GC-MS1 Major metaboliteMethylation or oxidationNot evaluated\[[@CIT0044]\]NSC 674495 (2-(4-Amino-3-methylphenyl) benzothiazole: *DF* 203)In vitroBreast cancer cell lines (MCF-7, T-47D, and MDA-MB-435) and renal cancer cell\
lines (TK-10, A498, and CAKI-1)--HPLC-spectro-fluorometry, ^1^H NMR1 Major metabolite for sensitive cell lines (T-47D, MDA-MB-435): (6c: 2-(4-amino-3-methylphenyl)-6 hydroxybenzothiazole)Hydroxylation6c: low anti-cancer activity against MCF-7 cell lines (IC~50~\>100 M)\[[@CIT0045]\]PAC-1 (4-benzyl-piperazin-1-yl)-acetic acid (3-allyl-2- Hydroxy-benzylidene)-hydrazineIn vivoMale Wistar rats (PO: 50 mg/kg)Urine, feces, bileHPLC-QTOF-MS, HPLC-IT-MS14 Metabolites for urine (M1-M7, M9-M11, M13-M16);\
3 Metabolites for feces (M1, M6, M13);\
4 Metabolites for bile (M4, M13, M14, M16)Debenzylation (M1);\
Hydroxylation (M2-M6);\
Dihydroxylation (M8--M12);\
Carboxylation (M7);\
Dihydrodiol formation (M13);\
Glucuronidation (M14);\
Hydroxylation + glucuronidation (M15-M16)Not evaluated\[[@CIT0046]\]In vitroRLM--12 metabolites (M1-M6, M8-M13)PaclitaxelIn vivoOvarian carcinoma patients (IV: 135 mg/m^2^)Plasma, urineHPLC-MS2 Metabolites for plasma (P1: 6α-hydroxypaclitaxel, P3: 7-epipaclitaxel);\
3 Metabolites for urine (U1: 6α-hydroxypaclitaxel, U2: 10-deacetylpaclitaxel, U4: 7-epipaclitaxel)Not identifiedNot evaluated\[[@CIT0047]\]PaclitaxelIn vitroLiver microsomes from:\
Sprague-Dawley & hairless rats (males, females), BALB/c & OF1 mice (males, females), male guinea-pigs, male rabbits, male dogs, male monkeys, and humans--HPLC-UV1 Metabolite for male & female SD and hairless RLM, male & female BALB/c MLM (3′*p*-hydroxypaclitaxel);\
2 Metabolites for male & female OF1 mice & male rabbits (6α hydroxypaclitaxel and 3′*p*-hydroxypaclitaxel);\
2 Metabolites for male dog (6α-hydroxypaclitaxel, 6α,3′*p*-dihydroxypaclitaxel) liver microsomes;\
3 Metabolites in male guinea-pigs, male monkey, human liver microsomes (6α-hydroxypaclitaxel, 3′*p*-hydroxypaclitaxel, 6α,3′*p*-dihydroxypaclitaxel)Mono-hydroxylation (3′*p*-hydroxypaclitaxel, 6α-hydroxypaclitaxel);\
Di-hydroxylation (6α,3′*p*-dihydroxypaclitaxel)Not evaluated\[[@CIT0048]\]In vivoMale Dunkin Hartley albino guinea-pigs (IV: 6 mg/kg)Bile2 metabolites (M1: 6α Hydroxypaclitaxel, M2: 3\'*p*-Hydroxypaclitaxel)PhenylbutyrateClinical trialHuman (PO: 0.36 mmol/kg (5 g/75 kg))Plasma, urineGC-MS3 Metabolites for both samples (phenylacetate, phenylacetylglutamine, phenylbutyrylglutamine)Not identifiedNot evaluated\[[@CIT0049]\]PhyllanthosideIn vivoMale CDF~1~ micePlasmaHPLC-UV1 Metabolite (M)AglyconeM: anticancer activity against human rhabdomyosarcoma cell lines (A204 cell lines) lower than parent compound with IC~50~ of 24 µM and 0.47 nM\[[@CIT0050]\]Sepin-1In vitroMLM, RLM, HLM--UHPLC-QTOF-MS7 Metabolites for all species (M1-M7)Reduction (M1, M2);\
Dimer formation (M3-M5);\
Cysteine conjugation (M6);\
Glutathione conjugation (M7)Not evaluated\[[@CIT0051]\]SN30000 (3-(3-Morpholinopropyl)-7,8-dihydro-6H-indeno\[5,6-e\] \[1,2,4\] triazine 1,4-dioxide: tirapazamine analog)In vivoFemale NIH-III mice (IP: 186 mg/kg)Plasma, liver, HT29 tumorLC-MS/MS19 Metabolites for plasma (M1-M19);\
16 Metabolites for liver (M3-M7, M9, M10-M19);\
19 Metabolites for tumor (M1-M19)Reduction;\
Oxidation;\
GlucuronidationM14: acute toxicity (hypothermia) similarly to SN30000\[[@CIT0006]\]TamoxifenIn vivoAthymic mice (PO and SC: 200 mg/kg/day, 50 mg/kg/day, and 12.5 mg/kg/day), Breast cancer patients (10 mg BID)SerumHPLC-UV2 Metabolites for mouse serum after PO and SC of 200 mg/kg/day and 50 mg/kg/day and patient serum (4-Hydroxytamoxifen and *N*-desmethyl tamoxifen);\
Higher level of metabolites with higher dosesHydroxylation (4-hydroxytamoxifen);\
*N*-demethylation (*N*-desmethyltamoxifen)Not evaluated\[[@CIT0052]\]TamoxifenIn vitroHuman liver homogenate, human hepatoblastoma (HepG2) cell lines--LC-ESI-MS6 Metabolites for human liver homogenate (M1-M5, M8);\
4 Metabolites for HepG2 (M2-M5)*N*-Di-desmethylation (M1);\
*N*-Desmethylation (M4);\
Hydroxylation (M2 and M3);\
*N*-oxidation (M5);\
*N*-Desmethylation + hydroxylation (M6, M7);\
*N*-oxidation + hydroxylation (M8)Not evaluated\[[@CIT0053]\]In vivoBreast cancer patients (PO: 60 mg OD or 30 mg OD \> 6 months)Plasma8 Metabolites (M1-M8; M8 only in patients who received long term \> 6 months)TamoxifenIn vivoFemale Rowett athymic nude rats (PO: 5 mg/kg/day or SC: 50 mg)Serum, liver, lung, retroperitoneal adipose tissue, kidneys, brain, muscle, heart, spleen, stomach, small intestine, uterus tissues2 Metabolites for all samples except adipose tissue (4-Hydroxytamoxifen, *N*-Desmethyltamoxifen) after 21 days PO;\
4-Hydroxytamoxifen for all samples except adipose tissue and uterus after 33 days PO;\
*N*-Desmethyltamoxifen for all samples except adipose tissue after 33 days PO;\
2 Metabolites for liver, lung, brain, heart, and kidney (4-Hydroxy tamoxifen and *N*-Desmethyltamoxifen) after 33 days SC;\
Level of metabolites detected in SC lower than POHydroxylation (4-Hydroxytamoxifen);\
Demethylation (*N*-Desmethyltamoxifen)Not evaluated\[[@CIT0054]\]TamoxifenClinical trialBreast cancer patients (PO: 20--40 mg/day)PlasmaUHPLC-QqQ-Quantum-MS and UHPLC-Exactive Plus Orbitap-MS40 Metabolites (1--23, 25--27, 29--36, 38, 39, 42--45)Demethylation + hydroxylation + glucuronidation (1, 9, 13, 19);\
Hydroxylation + glucuronidation (2, 11, 15, 18);\
Carboxylation + glucuronidation (3);\
Di-hydroxylation + oxidation + glucuronidation (4, 21);\
Di-methylation + tetra-hydroxylation + glucosylation (5);\
Demethylation + carboxylation (6);\
Di-hydrodiol (7);\
Carboxylation (8);\
Demethylation + hydroxylation (10, 25, 27.32, 44);\
Hydroxylation (12, 29, 30, 33);\
Hydroxylation + carboxylation (14);\
Di-hydroxylation (16, 17, 31); Hydroxylation + sulfation (20);\
Di-demethylation + tri-hydroxylation + glucoside (22,26);\
Di-demethylation + hydroxylation (23);\
E-tamoxifen (34);\
Di-demethylation (35);\
Demethylation + desaturation (36);\
N-demethylation (38);\
Desaturation (39);\
Hydroxylation + desaturation (42, 45);\
Adding NO molecule (43)Not evaluated\[[@CIT0055]\]TAS-102 (tipiracil hydrochloride (TPI) + trifluridine (FTD))Clinical trialAdvanced solid tumor patients (PO: 1000 nCi of \[^14^C\]-TPI)Plasma, urine, fecesHPLC-QqQ-MS1 Major metabolite for plasma, urine, and feces (6-hydroxyme-thyluracil (6-HMU))Not identifiedNot evaluated\[[@CIT0056]\]Advanced solid tumor patients (PO: 200 nCi of \[^14^C\]-FTD)1 Major metabolites for plasma (Trifluoromethyluracil (FTY));\
3 Major metabolites for urine (FTY, FTD Glu U3, FTD Glu U4)Glucuronidation (FTD Glu U3 and FTD Glu U4);\
Unidentified (FTY)TNP-470 (O-(chloroacetyl-carbamoyl) fumagillol)In vitroHuman hepatocyte, human liver, intestinal, kidney microsomes--HPLC-QqQ-MS6 Metabolites for cultured human hepatocytes (M1-M6: M2 and M5 = predominant metabolites of extracellular and intracellular, respectively);\
3 Metabolites for HLM (M1, M2, M4);\
2 Metabolites for intestine and kidney microsomes (M2, M4)Esterase (M4); Esterase + Epoxide hydrolysis (M2)Not evaluated\[[@CIT0057]\]TW01003 ((3E,6E)-3-Benzylidene-6-\[(5- hydroxypyridin-2-yl) methylene\] piperazine-2,5-dione)In vivoPig (IV) and male Wistar rats (IV: 7 mg/kg and PO: 36 mg/kg)Plasma (rat) and urine (pig)HPLC1 Metabolite for pig urine (TW-01003 sulfate);\
2 Metabolites for rat plasma after IV (TW-01003 sulfate (major), TW-01003 glucuronide);\
2 Metabolites after PO (TW-01003 sulfate, TW-01003 glucuronide (major))Sulfation (TW-01003 sulfate);\
Glucuronidation (TW-01003 glucuronide)Not evaluated\[[@CIT0058]\][^1] Table 2Metabolism Studies (Metabolite Profiling) of Small Molecules-Targeted Anticancer DrugsAnticancer DrugType of StudyBiochemical Tool/Animal/Human (Route: Dose)Type of SampleAnalytical TechniqueOutcomeRef.MetaboliteMetabolic PathwayEfficacy/Toxicity of MetaboliteAZD8055In vitroRLM--UHPLC-IT-MS5 Metabolites (M1-M5)Demethylation (M1);\
Hydroxylation (M2);\
Oxidation (M3 and M4);\
Di-oxidation (M4);\
Morpholine ring opened\
AZD8055 (M5);\
Demethylation + glucuronidation (M6);\
Hydroxylation + glucuronidation (M7);\
Glucuronidation (M8)Not evaluated\[[@CIT0059]\]In vivoMale Sprague-Dawley rat (PO: 20 mg/kg)Plasma, urine, feces8 Metabolites in all samples (M1-M8)BrivanibIn vitroPooled HLM and cytosol, human cDNA-expressed CYP, and human recombinant SULTs-HPLC-LTQ-IT-MS6 Metabolites (M7, M19, M25, M26, M31 M33)Hydroxylation (M7);\
Oxidation (M26, M31);\
Sulfation (M25);\
Oxidation + sulfation (M19, M33)Not evaluated\[[@CIT0060]\]EPZ-5676 (Pinometostat)In vitroRLM, DLM, HLM, and rat, dog, and human hepatocyte-HPLC-RD-IT-TOF-MS6 Metabolites for RLM (EPZ007769, EPZ007309, M3, M4, M6, M8);\
1 Metabolite for DLM (EPZ007769);\
5 Metabolites for HLM (EPZ007769, EPZ007309, M3, M4, M6);\
7 Metabolites for rat hepatocyte (EPZ007769, EPZ007309, M1a/b, M2, M3, M6, M8);\
4 Metabolites for dog hepatocyte (EPZ007769, EPZ007309, M1a/b, M2);\
5 Metabolites for human hepatocyte (EPZ007769, EPZ007309, M1a/b, M2, M6)Mono-hydroxylation (EPZ007769);\
Mono-hydroxylation + oxidation (EPZ026194);\
Dealkylation of *N*-isopropyl (EPZ007309);\
*N*-dealkylation + tri-oxidation (M1a/b);\
*N*-dealkylation + di-oxidation (M2);\
*N*-dealkylation + mono-oxidation (M3);\
*N*-dealkylation + keto-oxidation (M4);\
Mono-oxidation + dehydrogenation (M5);\
Mono-oxidation (M6 and M7);\
*N*-dealkylation + hydroxylation (M8);\
*N*-dealkylation (M9, M10 and M11);\
Oxidative cleavage of ribose ring (M12);\
*N*-dealkylation + oxidation (M13)Not evaluated\[[@CIT0061]\]In vivoSprague-- Dawley rats (IV: 30 mg/kg/day (100 µCi/kg)) and Beagle dogs (IV: 10 mg/kg/day (200 µCi/animal))Plasma, urine, feces, bile (rat and dog)2 Metabolites for rat plasma (EPZ007769, EPZ026194);\
3 Metabolites for rat urine (EPZ007769, EPZ026194, M5);\
2 Metabolites for dog urine (EPZ007769, EPZ026194);\
4 Metabolites for rat feces (EPZ007769, EPZ026194, M7, M9);\
4 Metabolites for dog feces (EPZ007769, EPZ026194, M7, M8);\
4 Metabolites for rat bile (EPZ007769, EPZ026194, M5, M6);\
2 Metabolites for dog bile (EPZ007769, EPZ026194)Phase I clinical trialCancer patient (IV: 36 mg/m^2^/day)Plasma, urine2 Metabolites for plasma (EPZ007769, EPZ007309);\
10 Metabolites for urine (EPZ007769, EPZ007309, M1a/b, M2, M8-M13)HM781-36B (1-\[4-\[4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy\]-piperidin-1-yl\] prop-2-en-1-one hydrochloride)In vivoMale beagle dogs (PO: 8 mg/kg)Urine, feces, plasmaHPLC-UV, LC-ESI-IT-MS, LC-QTOF-MS/MS4 Metabolites for plasma (M1, M2, M8, M10);\
3 Metabolites for urine and feces (M1, M2, M10)Di-hydroxylation (M1);\
Demethylation (M2);\
*N*-Oxidation (M3, M9);\
Defluorination + hydroxylation (M4);\
Dechlorination + hydroxylation (M5);\
Demethylation + di-hydroxylation (M6);\
*N*-oxidation + di-hydroxylation (M7);\
Hydroxylation (M8);\
Deacryloylpiperideine (M10)Not evaluated\[[@CIT0005]\]In vitroDLM, HLM, Recombinant CYP enzymes (3A4, 2D6, 1A2, 2C9, 2C19, and 2E1)--10 Metabolites for HLM (M1-M10);\
4 Major metabolites for DLM (M1, M2, M8, M10);\
10 Metabolite for rCYP3A4 (M1-M10);\
1 Metabolite for rCYP2D6 (M2)ImatinibIn vitroInsect-cell microsomes that contained cDNA expressing human CYP isozymes (CYP1A1, 1A2, 1B1, 4F2, 4F3A/B, 3A4)--HPLC-LTQ-MS6 Metabolites (*N*-demethyl-, Unk\#3, Unk\#5, Unk\#6, Unk\#7, Unk\#8) for CYP3A4;\
4 Metabolites for CYP1A1 (*N*-demethyl-, Unk\#3, Unk\#5, Unk\#7);\
1 Metabolite for 1A2 (7);\
2 Metabolites for 1B1 (5 and 7);\
2 Metabolites for 4F2 (*N*-demethyl- and 5);\
2 Metabolites for 4F3A and 4F3B (*N*-demethyl- and 5)*N*-demethylation (*N*-demethyl-);\
Hydroxylation (Unk\#3 and Unk\#5);\
*N*-oxidation (Unk\#6, Unk\#7, and Unk\#8)Not evaluated\[[@CIT0062]\]ImatinibIn vitroHLM--HPLC-ESI- QqQ-MS28 Metabolites (1--17, 19--24, 27--29, 32, 33)Hydroxylation/*N*-oxidation (3, 8, 9,11--14, 18, 19, 22--24, 32);\
Hydroxylation/*N*-oxidation + *N*-demethylation (7, 10, 16, 20);\
Glucuronidation (27--29, 33);\
Other (2, 6, 31)Not evaluated\[[@CIT0063]\]Clinical trialCancer patients (PO: 400-800 mg)Plasma31 Metabolites (1--14, 16, 18--20, 22--33)IrosustatIn vitroRLM, DLM, MLM, HLM, Rats and dogs hepatocytes--HPLC-UV, HPLC-MS and ^1^H NMRRLM:\
12 Metabolites for male (M7-M11, P-24, M13-M16, M18, 667-coumarin) & female (M7-M11, M13-M16, M18, P36, 667-coumarin);\
DLM:\
14 Metabolites for male & female (P-14, M7-M10, P-23, P-24, M13-M16, M18, P-36, 667-coumarin);\
MLM:\
9 Metabolites for male (P-14, M7-M10, P-24, M13, M14, M16);\
8 Metabolites for female (P-14, M7-M10, P-24, M13, M16);\
HLM:\
14 Metabolites for male & female (M7-M11, P-23, P-24, M13-M16, M18, P-36, 667-coumarin);\
Hepatocytes:\
6 Metabolites for male rat (M2, M3, M7, M12, M17, 667-courmarin);\
2 Metabolites for male dog (M12, M17);\
7 Metabolites for female human (M1, M2, M12, M16, M17, 667-coumarin)Hydroxylation (M7, M9, M13, M14, M18);\
Desulfamoylation (667-coumarin);\
Hydroxylation + desulfamoylation (M8, M15, M16, and P-36);\
Hydroxylation + desulfamoylation + glucuronidation (M1, M2, and M12);\
Hydroxylation + desulfamoylation + sulfation (M17);\
Not identified (M11)Not evaluated\[[@CIT0064]\]JNJ-38877605In vitroRat, rabbit, dog, monkey, and human hepatocytes\
and liver subcellular fractions--LC-MS12 Metabolites for all species hepatocyte and liver subcellular fraction (M1-M12)Hydroxylation (M1, M3);\
*N*-demethylation (M2);\
Oxidation (M4);\
*N*-demethylation + hydroxylation (M5-M7);\
Hydroxylation + glucuronidation (M8);\
*N*-demethylation + hydroxylation + glucuronidation (M9 and M11);\
*N*-demethylation + glucuronidation (M10);\
*N*-demethylation + oxidation + glutathione conjugation (M12)M1-M5: crystal formation in kidney;\
M10: renal toxic metabolites in rabbit and human (species-specific toxic metabolite)\[[@CIT0065]\]In vivoRat (PO: 2.5 mg/kg), dog (PO: 2.5 mg/kg), and rabbit (PO: 100 mg/kg)Plasma, urine, feces6 Metabolites for rat plasma, urine, feces (M1-M6);\
4 Metabolites for dog plasma, urine, feces (M1-M4);\
7 Metabolites for rabbit plasma, urine, feces (M2-M7, M10)Phase I clinical trialCancer patients (PO: 60 mg)Plasma, urine4 Metabolites for human plasma and urine (M2, M3, M5, and M10)LenvatinibIn vivoMale Sprague Dawley rats (PO: 30 mg (12.685 MBq)/kg), Cynomolgus monkey (PO: 30 mg (12.685 MBq)/kg), and Solid tumor or lymphoma patients (PO: 24 mg (100 μCi))Plasma, urine, feces and bileHPLC-LTQ-IT-MS, HPLC-LTQ-Orbitrap-MS27 Metabolites for rat (M1-M3, M5, MET5, MET6-MET8, MET10, MET12, MET15, MET17, MET18, MET19a, MET19b, MET20.1, MET21-MET24, MET24.1, MET27, MET29, MET29.1, MET30, MET32, MET34, MET35);\
24 Metabolites for monkey (M1-M3, M2ʹ, M3ʹ, M5, MET3, MET4, MET9, MET10, MET13, MET16, MET18, MET20, MET20.1, MET22, MET23, MET24.1, MET26, MET27, MET29.1, MET30, MET32, MET34);\
18 Metabolites for human (M1-M3, M2ʹ, M3ʹ, M5, MET3, MET4, MET20.1, MET22, MET24, MET27, MET29.1, MET30-MET32, MET34 MET36)Oxidation/hydroxylation (M3ʹ, MET34, MET35);\
Di-oxidation/Di-hydroxylation (MET36);\
*N*-oxidation (M3);\
Dealkylation (M1, M2);\
Hydrolysis (M5, MET30, MET32);\
Hydrolysis + oxidation/hydroxylation (MET29);\
Dealkylation + oxidation/hydroxylation (M2ʹ);\
Oxidation/hydroxylation + glucuronidation (MET31);\
Dealkylation + glucuronidation (MET27);\
Dealkylation + glucuronidation + hydrolysis (MET24);\
Hydrolysis/*O*-dearylation (MET29.1);\
Hydrolysis/*O*-dearylation + other conjugation (MET20.1, MET24.1);\
Glutathione/cysteine conjugation and subsequence biodegradation (MET7, MET8, MET10, MET12, MET13, MET15, MET18, MET19b, MET26);\
Glutathione/cysteine conjugation and subsequence biodegradation + intramolecular arrangement (MET19a and MET21);\
Glutathione/cysteine conjugation and subsequence biodegradation + intramolecular arrangement + dimerization (MET16, MET17, MET20, MET22, MET23);\
Glutathione/cysteine conjugation and subsequence biodegradation + intramolecular arrangement + glutathione/cysteine conjugation and subsequence biodegradation (MET3, MET4, MET6, MET9)Not evaluated\[[@CIT0066]\]NeratinibIn vitroRat hepatocytes-UHPLC‐DAD, UHPLC-Quadrupole-Orbitrap‐MS12 Metabolites (M1-M12)*O*‐Dealkylation + glutathione conjugation (M1, M2);\
*O*‐Dealkylation (M3);\
Oxygenation + glutathione conjugation (M4, M5);\
Glutathione conjugation (M6, M7);\
Oxygenation (M8);\
*N*‐Acetylcysteine conjugation (M9, M11);\
*N*‐demethylation (M10);\
*N*‐oxygenation (M12)Not evaluated\[[@CIT0067]\]In vivoMale Sprague--Dawley rats (PO: 20 mg/kg)Bile, urine12 Metabolites for bile (M1-M12);\
6 Metabolites for urine (M3 and M8-M12)ON 013100 ((E)-2,4,6-trimethoxystyryl-3-hydroxy-4-methoxybenzyl sulfoneIn vitroColon cancer cell lines (drug resistant, colo-205, and drug sensitive, colo-320--HPLC-MS, HPLC-MS/MSE-form and Z-form of glucuronidation of ON 013100 were detected in colo-205 incubation system but not colo-320GlucuronidationNot evaluated\[[@CIT0068]\]OsimertinibIn vitroHLM, MLM--UHPLC-MS/MS7 Metabolites for HLM (DM-1: AZ5104, DM-2:AZ7550, OH-1, OH-2, OH-3, OH-4, OH-5);\
4 Metabolites for MLM (DM-1, DM-2, OH-2, OH-4)*N*-Demethylation (DM1 and DM-2);\
Oxidation (OH-1, OH-5);\
*N*-oxidation (OH-2, OH-4)Not evaluated\[[@CIT0069]\]PimasertibClinical trailCancer patients (PO: 60 mg)Plasma, urine, and fecesUPLC-MS2 Metabolites (M445, M554)Oxidation (M445);\
Phosphoethanolamine conjugation (M554)Not evaluated\[[@CIT0070]\]TKI258 (Dovitinib)CohortCancer patients (PO: 500 mg)Plasma, Urine, and FecesHPLC, LTQ-Orbitrap-MS3 Metabolites for plasma (M8, M9, M26);\
6 Metabolites for urine (M4, M5, M8, M9, M22, M26);\
8 Metabolites for feces (M2, M5, M6, M8, M10, M26, M32, M33)Fluorobenzyl ring hydroxylation (M6, M10);\
*N*-demethylation (M8);\
Piperazine *N*-oxide (M9);\
Glucuronidation (M26);\
Piperazine *N*-dealkylation (M30);\
2 (+O, −2H) on piperazine (M32);\
(+O, −2H) on piperazine (M33);\
Fluorobenzyl ring hydroxylation + sulfation (M2 and M5);\
Fluorobenzyl ring hydroxylation + glucuronidation (M4);\
*N*-demethylation + hydroxylation + sulfation (M23)Not evaluated\[[@CIT0004]\][^2] Table 3Metabolism Studies (Metabolite Profiling) of Herb-Derived Compounds with Anticancer ActivitiesAnticancer DrugType of StudyBiochemical Tool/Animal/Human (Route: Dose)Type of SampleAnalytical TechniqueOutcomeRef.MetaboliteMetabolic PathwayEfficacy/Toxicity of MetaboliteAlantolactone (*Inula helenium* L.)In vivoMale Sprague--Dawley rats (PO: 100 mg/kg)Urine, feces, bileUPLC-TOF-MS11 Metabolites for urine (M1-M5, M10-M11, M14-M16, M18);\
10 Metabolites for bile (M1-M4, M8, M12, M25, M33, M43-M44);\
38 Metabolites for feces (M1-M13, M17-M25, M27-M31, M33, M35-M44)Oxidation (M1-M9);\
Di-oxidation (M10-M11);\
Demethylation (M12-M13);\
Demethylation to carboxylic acid (M14-M15);\
Hydration (M16);\
Hydrogenation (M17-M18);\
Addition of H~2~S (M19-M20);\
Addition of H~2~S + oxidation (M21-M23);\
AL~2~-S (M24-M25: one sulfur-containing dimer metabolites of alantolactone);\
AL~2~-S + oxidation (M27-M31);\
AL~2~-SS (M33: two sulfur-containing dimer metabolites of alantolactone);\
AL~2~-SS + oxidation (M35-M39);\
AL~2~-SSS (M40: three sulfur-containing dimer metabolites of alantolactone);\
AL~2~-SSSS (M41: four sulfur-containing dimer metabolites of alantolactone);\
AL~2~-SSSSS (M42: five sulfur-containing dimer metabolites of alantolactone);\
Cysteine conjugation (M43);\
*N*-acetylcysteine conjugation (M44)Not evaluated\[[@CIT0009]\]*Astragali Radix* water extract (containing calycosin-7-β-glucoside, formononetin, calycosin, ononin, astragaloside IV)In vivoMale Sprague--Dawley rats (PO: 4 g/kg and 16 g/kg *Astragali Radix* water extract)PlasmaUHPLC-MS/MS4 Metabolites (calycosin-7-β-glucoside-3ʹ-glucuronide for calycosin-7-β-glucoside, formononetin-3ʹ-glucuronide for formononetin; calycosin-3ʹ-glucuronide for calycosin, daidzein-3ʹ-glucuronide);\
No metabolites for ononin and astragalosideGlucuronidationNot evaluated\[[@CIT0071]\]Calphostin C (*Cladosporium cladosporoides*)In vitroCD-1 MLM--LC-MS1 Metabolite (after incubating liver microsomes with porcine esterase)Breaking the ester bondNot evaluated\[[@CIT0072]\]In vivoFemale CD-1 mice (IP: 40 mg/kg)Plasma1 MetaboliteCAT (3,6,7-trimethoxyphenan-throindolizidine (isolated from *Tylophora atrofolliculata*))In vivoMale Wistar rats (PO: 6 mg/kg)UrineRRLC-ESI-QTOF-MS21 metabolites (M1-M21)Di-demethylation + di-glucuronidation (M1-M3);\
Di-demethylation + glucuronidation (M4-M9);\
Demethylation + glucuronidation (M10-M12);\
Di-demethylation (M13-M15);\
Demethylation (M16-M18);\
Oxidation (M19);\
Hydroxylation (M20-M21)Not evaluated\[[@CIT0073]\]Dimethoxycurcumin (Curcumin analog)In vitroMLM (male CD-1), HLM (CYPream)--HPLC-QTRAP, HPLC-QqQ-LIT-MS8 Metabolites for MLM (369, 371, 383, 385, 399, 401, 559, 561);\
7 Metabolites for HLM (369, 383, 385, 399, 401, 559, 561)Di-*O-*demethylation (369);\
Di-*O-*demethylation + hydrogenation (371);\
*O*-demethylation (383);\
*O*-demethylation + hydrogenation (385);\
Hydrogenation (399);\
Di-hydrogenation (401);\
*O*-demethylation + glucuronidation (559);\
*O*-demethylation + hydrogenation + glucuronidation (561)Not evaluated\[[@CIT0074]\]Fisetin (flavonoid compound)In vivoFemale C57BL/6J mice (IP: 223 mg/kg)PlasmaHPLC-MS/MS3 Metabolites (M1, M2, M3: geraldol)Glucuronidation (M1, M2); Methoxylation (M3)M3: 2.5 and 1.1-fold higher cytotoxic effect against LLC cell line (Lewis carcinoma) and EAhy 926 cell line (endothelial cell) compared to fisetin, respectively;\
M3 exhibited 1.5-fold fold higher cytotoxic effect against NIH 3T3 cell line (normal cell)\[[@CIT0075]\]Flavone-8-acetic acid (FAA)In vitroHLM, MLM expressing CYP enzyme induced by Aroclor 1245--HPLC-UV, HPLC-UV-MS6 Metabolites for MLM (M1: 3ʹ,4ʹ-dihydrodiol-FAA, M2: 5.6-epoxy-FAA, M3a: 4ʹ-OH-FAA, M3b: 3ʹ-OH-FAA, M3c: 3ʹ,4ʹ-epoxy-FAA, M4: 6-OH-FAA);\
One human liver microsome (sample 14) produced M3a and another human liver microsome (sample 15) produced 3 metabolites of M1, M3a, M3c: 3ʹ,4ʹ-epoxy-FAAEpoxide hydrolase reaction (M1);\
Epoxidation (M2, M3c);\
Hydroxylation (M3a, M3b, M4)Interspecies difference metabolism could involve with difference anticancer activity\[[@CIT0076]\]Furanodiene (Rhizoma Curcumae)In vitroRat liver S9, RLM--HPLC-ESI-MS, HR-ESI-MS, and ^1^H NMR, ^13^C NMR, 2D NMR6 Metabolites for rat liver S9 (M1: 1β,10α,4α,5β-diepoxy-8α-hydroxy-glechoman-8α,12-olide, M2: 2β-hydroxyl-aeruginolactone, M3: 14-hydroxyl-aeruginolactone, M4: 1β,8β-dihydroxyeudesm-4(14),7(11)-dien-8α,12-olide or 1β,8β-dihydroxyeudesm-4,7(11)-dien-8α,12-olide, M5: 1β,8β-dihydroxyeudesm-3,7(11)-dien-8α,12-olide M6: aeruginolactone);\
1 Metabolite for RLM (M6)Oxidation (M6);\
Oxidation + Hydroxylation (M2, M3);\
Epoxidation (M1);\
Epoxidation + new bond formation (M4, M5)Not evaluated\[[@CIT0077]\]In vivoMale Sprague-Dawley Rat (PO: 100 mg/kg)Bile, urine, feces6 Metabolites for bile and urine (M1-M6);\
1 Metabolite for feces (M6)(-)-grandisin (extracted from *Piper solmsianum*)In vitroHLM--GC-MS and LC-MS4 Metabolites (M1: 4-*O*-demethylgrandisin, M2: 4,4′-di-*O*-demethylgrandisin, M3: 3,4-di-*O*-demethylgrandisin or 3,5-di-*O*-demethylgrandisin, M4: 3-*O*-demethylgrandisin)DemethylationNot evaluated\[[@CIT0002]\]Irisflorentin (*Belamcanda chinensis*)In vitroRLM--HPLC-UV7 Metabolites (M1: 6,7-Dihydroxy-5,3′,4′,5′-tetramethoxy isoflavone, M2: Irigenin,\
M3: 5,7,4′-Trihydroxy-6,3′,5′ trimethoxy isoflavone, M4: 6,7,4′-Trihydroxy-5,3′,5′-trimethoxy isoflavone, M5: 6,7,5′-Trihydroxy-5,3′,4′-trimethoxy isoflavone; M6 and M7: unidentifiedCleavage of methylene acetyl group (M1);\
Adding of hydroxyl and methoxyl groups (M2-M5)M1 & M2: 4.6 and 8.4-fold cytotoxic activities against DU145 and 4- and 8.2-fold against MCF-7 cell lines compared with parent compound.\[[@CIT0078]\]Leelamine (bark of pine tree)In vitroHLM--LC-MS/MS1 Metabolite in the presence of NADPH generation systemHydroxylationNot evaluated\[[@CIT0007]\]In vivoMale ICR mice (IP: 10 mg/kg)Urine, feces1 Metabolite for urine not in fecesMPD (Methyl protodioscin: isolated from *Dioscorea collettii* var. *hypoglauca*))In vivoMale Sprague-Dawley rats (PO: 80 mg/kg)Urine^1^H NMR, ^13^C NMR, HRSI-MS10 Metabolites\
(M1: Dioscin,\
M2: pregna-5,16-dien-3β-ol-20-one-*O*-α-L-rhamnopyranosyl-(1→2)-\[α-L-rhamnopyranosyl-(1→4)\]-β-D- glucopyranoside,\
M3: diosgenin,\
M4: protobioside,\
M5: methyl protobioside,\
M6: 26-*O*-β-D-glucopyrannosyl (25*R*)-furan-5-ene-3β,22α, 26-trihydroxy-3-*O*-α-L-rhamnopy-ranosyl-(1→ 4)-β-D-glucopyranoside,\
M7: 26-*O*-β-D-glucopyranosyl (25*R*)-furan-5-ene-3β,26-dihydroxy-22-methoxy-3-*O*-α-L-rhamnopyranosyl-(1→4)-β-D-glucopyranoside,\
M8: prosapogenin A of dioscin,\
M9: prosapogenin B of dioscin,\
M10: diosgenin-3-*O*-β-D-glucopyranoside)Dealkylation;\
Dehydration;\
OxidationAll metabolites: lower cytotoxic activities against human HepG2, NCI-H460, MCF-7 and HeLa cell lines than parent drug & MPD. However, M1 and M4 exhibited strong anti-cancer activities against HepG2 (M1), NCI-H460 (M1, M4), and HeLa cell lines (M4).\[[@CIT0079]\]Oridonin (ORI) (Diterpinoid of *Isodon rubescens*)In vivoMale Spraque-Dawley rats (PO: 10 mg/kg)Bile, urineUPLC-QqQ TOF-MS17 Metabolites for bile (M1-M4, M6-M18);\
10 Metabolites for urine (M1-M6, M12, M14-M16)Hydroxylation (M1-M3);\
Ketone Formation (M4);\
Hydroxylation + hydration (M5);\
Dehydroxylation (M6-M7);\
Di-dehydroxylation (M8-M11);\
Dehydration (M12);\
Dehydroxylation + dehydration (M13);\
Didehydroxylation + oxidized to carboxylic acid (M14);\
Desaturation + oxidized to carboxylic acid (M15);\
Hydration (M16);\
Dehydroxylation + glucuronidation (M17, M18)Not evaluated\[[@CIT0080]\]Quercetin (flavonoid)In vitroHuman hepatocellular carcinoma cell lines (HepG2)--HPLC-RD1 Metabolite (4)*O*-methylationNot evaluated\[[@CIT0081]\]Trabectedin (ET-743: isolated compound from *Ecteinascidia turbinata*)Clinical trialCancer patients (IV: 1 mg of trabectedin (2.5 MBq \[^14^C\] trabectedin (70 µCi)))Urine and fecesHPLC-QqQ-MS and LC-LSC8 Fractions for urine (U1-U8); 10 Fractions for feces (F1-F10)\
(U4, F3, and F5: ETM-204; U5 and F6: ETM-217; U6 and F7: ET-759A and ET-731; U7 and F9: ET-745, ETM-259; U8 and F10: ET759B)Dehydroxylation (ET-745);\
Dehydroxylation +demethylation (ET-731);\
Oxidation (ET-759A);\
Breaking up of the molecule to the individual tetrahydroisoquinoline\
subunits (ETM259 and ETM204);\
ETM-259 + acetate ester hydrolysis (ETM217)Not evaluated\[[@CIT0082]\]Yuanhuapine (Isolated from *Daphne genkwa*)In vivoMale Sprague-Dawley rats (Oral: 5 mg/kg)UrineUPLC-QTOF-MS12 Metabolites (M1-M12)Hydroxylation (M1-M4);\
Di-hydroxylation (M5, M6);\
Tri-hydroxylation (M7);\
Hydroxylation + glucuronidation (M8);\
Methylation + di-hydroxylation (M9);\
(Hydroxylation + methylation) + (hydroxylation + glucuronidation) (M10);\
Reduction + 2(Cysteine conjugation) (M11);\
Hydration + (S-Cysteine conjugation) (M12)Not evaluated\[[@CIT0003]\]Ziyuglycoside II (*Sanguisorba officinalis* L.)In vitroRat liver homogenate--LC-QTOF-MS16 metabolites (H-M1-H-M16)Glucuronidation (H-M1);\
Glucose conjugation (H-M2-H-M4);\
Dehydration + glucuronidation (H-M5);\
Formolation of ziyuglycoside II (adding CO: H-M6);\
Oxidation + reduction (H-M7);\
Dehydrogenation (H-M8);\
Demethylation (H-M9);\
Dehydration (H-M10, H-M11);\
Dearabinosylation + oxidation (H-M12, H-M13);\
Dearabinosylation (H-M14);\
Dearabinosylation + reduction (H-M15, H-M16)Not evaluated\[[@CIT0083]\]In vivoMale Sprague-Dawley rats (Oral: 50 mg/kg)Urine, fecesUFLC-QTOF-MS10 Metabolites for urine (U-M1-U-M10);\
10 Metabolites for feces (F-M1 and F-M10)Glucuronidation + glycosylation (U-M1);\
Glucuronidation + deglycosylation + decarboxylation + dihydroxylation (U-M2);\
U-M2 + deoxidation + methylation (U-M3);\
Glucuronidation + loss of C~2~H~2~O (U-M4);\
U-M4 + deoxidation + methylation (U-M5);\
Decarboxylation (U-M7);\
Glucosylation (U-M6);\
Dearabinosylation (U-M9 and F-M9);\
Dearabinosylation + oxidization (U-M8, F-M5, F-M6);\
Dearabinosylation +dehydrogenation (U-M10);\
Oxidation (F-M1); F-M1 + dehydrogenation (F-M2);\
Dehydration (F-M3and F-M4);\
Dearabinosylation + loss of CO (F-M7);\
Dearabinosylation + demethylation (F-M8);\
F-M9 + dehydrogenation (F-M10)[^3] Table 4Activities of Conventional Anticancer Drugs, Synthetic Anticancer Candidates, Small Molecules Targeted Therapy, Herb-Derived CompoundsCompoundsReferencesActivityConventional anticancer drugsAM6-36 (3-amino-6-(3′-aminopropyl)-5H-indeno\[1,2-c\] isoquinoline-5,11-(6H) dione)\[[@CIT0013]\]Antiproliferation (Breast cancer cell line (MCF-7))ARQ 501 (synthetic β-lapachone)\[[@CIT0015]\]Anticancer (Pancreatic, head and neck cancer, and leiomyosarcoma)Cabazitaxel\[[@CIT0016]\]Anticancer (Prostate cancer)Capecitabine\[[@CIT0017]\]Anticancer (Colorectal cancer)Carbendazim\[[@CIT0018]\]Apoptotic induction, Antitumor (Solid tumor)CI-941(losoxantrone)\[[@CIT0019]\]Anticancer (Breast and prostate cancers)CP-31398 (*N'*-\[2-\[2-(4-methoxyphenyl) ethenyl)-4-quinazolinyl\]-*N, N*-dimethyl-1,3-propanediamine\
Dihydrochloride)\[[@CIT0084],[@CIT0085]\]Antiproliferative (Colon cancer (DLD1) and lung cancer (H460) and intestinal tumor cells)CPA\
(Cyproterone acetate)\[[@CIT0022]\]Anticancer (Prostate cancer)Cisplatin\[[@CIT0020]\]Anticancer (Testicular, ovarian, bladder, cervical, esophageal, small\
cell lung, head and neck cancers)Crisnatol\[[@CIT0023]\]Antitumor (Hepatoma)Cyclophosphamide\[[@CIT0024],[@CIT0086]\]Anticancer (Leukemia, lymphoma, breast, lung, prostate, and ovarian cancers)DFS (Trans-2,6-difluoro-4′-(*N, N*-dimethylamino) stilbene: Stilbene analog)\[[@CIT0025]\]Antitumor (Colorectal cancer)5ʹ-dFUrd and 5ʹ-dFUR (5ʹ-deoxy-5-fluorouridine)\[[@CIT0026],[@CIT0027]\]Anticancer (Gastric, colorectal, and breast cancer)EAPB0203\[[@CIT0028]\]Antitumor (Melanoma, T lymphoma, colon, and breast cancers)EAPB0503\[[@CIT0029]\]Antitumor (Melanoma, T lymphoma, and colon cancer)E-DE-BPH (E-3,4-bis (4-Ethylphenyl) hex-3-ene: stilbene derivatives)\[[@CIT0030]\]Anticancer2-F-araA (9-β-D-arabinofuranosyl-2-fluoroadenine)\[[@CIT0031]\]Antitumor (Leukemia)Flutamide\[[@CIT0032]\]Antiandrogen (Prostate cancer)4-Hydroxyanisole\[[@CIT0033]\]Anticancer (Malignant melanoma)Irinotecan\[[@CIT0034]\]Anticancer (Colon and lung cancer)Ixabepilone\[[@CIT0087]\]Anticancer (Metastatic breast cancer)JM216\[[@CIT0036]\]Antitumor (Human ovarian carcinoma cell model)KO2 (Morpholine-urea-Phe-Hphe-vinylsulfone)\[[@CIT0037]\]Inhibit cancer progress by inhibiting potent cysteine proteaseLaromustine\[[@CIT0038]\]Anticancer (Leukemia)2-Methoxyestradiol\[[@CIT0039]\]Anticancer (Metastatic breast cancer, prostate cancer, and various tumors)Mitomycin C\[[@CIT0088]\]Anticancer (Bladder, colon, and breast cancers)NB-506\
(6-*N*-formylamino-12,13-dihydro-1,11-dihydroxy-13-(b-D-glucopyranosil) 5*H*-indolo \[2,3-*a*\]pyrrolo \[3,4-*c*\]carbazole-5,7(6*H*)-dione)\[[@CIT0041],[@CIT0089]\]Antitumor (lung and colon cancers, and metastatic cells)9NC (9-Nitro-20(*S*)-camptothecin)\[[@CIT0090]\]Anticancer (Ovarian, tubal, and peritoneal cancer)NSC 141549 (4ʹ-(9-Acridinylamino) methanesulfon-rn-anisidide *(rn* -AMSA))\[[@CIT0043]\]Antitumor (L1210 leukemia and Lewis lung carcinoma)NSC 652287 (2,5-bis(5-hydroxymethyl-2-thienyl) furan)\[[@CIT0044],[@CIT0091]\]Antiproliferative (renal carcinoma cells)NSC 674495 (2-(4-Amino-3-methylphenyl) benzothiazole: *DF* 203)\[[@CIT0045]\]Antitumor (Breast cancer (MCF-7 and MDA 468) cells models)PAC-1 (4-benzyl-piperazin-1-yl)-acetic acid (3-allyl-2- Hydroxy-benzylidene)-hydrazine\[[@CIT0046],[@CIT0092]\]Antitumor (colon cancer cell models)Paclitaxel\[[@CIT0047]\]Anticancer (Breast, lung, head, neck, and ovarian cancers)Phenylbutyrate\[[@CIT0093]\]Antitumor (Human prostate cancer, hepatocarcinoma and hepatoblastoma models), Anticancer (Acute myelogenous leukemia)Phyllanthoside\[[@CIT0050]\]Antitumor (BI6 melanoma and P388 leukemia)Sepin-1\[[@CIT0051]\]Antiproliferative (Breast cancer, leukemia, and neuroblastoma), Antitumor (breast carcinoma), Apoptotic inductionSN30000 (3-(3-Morpholinopropyl)-7,8-dihydro-6H-indeno\[5,6-e\] \[1,2,4\] triazine 1.4-dioxide: tirapazamine analog)\[[@CIT0006],[@CIT0094]\]Antiproliferative (Human colon cancer (HT29) and cervical (SiHa) cancer cells), Antitumor (HT29 and SiHa cancer cells models)Tamoxifen\[[@CIT0054],[@CIT0055]\]Antiestrogen (Breast cancer)TAS-102 (tipiracil hydrochloride (TPI) + trifluridine (FTD))\[[@CIT0056]\]Anticancer (Metastatic colorectal cancer)TNP-470 (O-(chloroacetyl-carbamoyl) fumagillol)\[[@CIT0057]\]Antitumor (B16 BL6 melanoma, M 5076 reticulum cell sarcoma, Lewis lung carcinoma, Walker 256 carcinoma), Anticancer, AntiangiogenesisTW01003 ((3E,6E)-3-Benzylidene-6-\[(5-hydroxypyridin-2-yl) methylene\] piperazine-2,5-dione)\[[@CIT0058]\]Antitumor, AntiangiogenesisSmall molecules-targeted anticancer drugsAZD8055\[[@CIT0059]\]Antiproliferation, Apoptotic induction, and Migration reduction (Leukemia, cervical, breast cancer, and laryngeal carcinoma)Brivanib\[[@CIT0060],[@CIT0095]\]Anticancer (Hepatocellular carcinoma)EPZ-5676 (pinometostat)\[[@CIT0061]\]Anticancer (Leukemia)HM781-36B (1-\[4-\[4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy\]-piperidin-1-yl\] prop-2-en-1-one hydrochloride)\[[@CIT0005]\]Anticancer (Advanced solid tumors i.e. non-small-cell lung cancer (NSCLC) patients with EGFR mutation (T790M), breast, and gastric cancer)Imatinib\[[@CIT0062],[@CIT0063]\]Anticancer (Chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST))Irosustat\[[@CIT0064]\]Antitumor (Breast cancer model), Anticancer (Breast cancer)JNJ-38877605\[[@CIT0065]\]Antitumor (Prostate, non-small-cell lung, and gastric cancer and glioblastoma cells models)Lenvatinib\[[@CIT0066]\]Anticancer (Hepatocellular carcinoma, melanoma, renal carcinoma, non-small-cell lung carcinoma, glioblastoma multiforme, ovarian and endometrial carcinoma)Neratinib\[[@CIT0067]\]Anticancer (Breast cancer)ON 013100 ((E)-2,4,6-trimethoxystyryl-3-hydroxy-4-methoxybenzyl sulfone (Kinase inhibitor))\[[@CIT0068]\]Anticancer (Lymphoma and acute lymphoid leukemia)Osimertinib\[[@CIT0069]\]Anticancer (Non--small cell lung cancer)Pimasertib\[[@CIT0070]\]Anticancer (Non-small cell lung, colorectal cancer, and head and neck squamous cell carcinoma)TKI258 (dovitinib)\[[@CIT0096]\]Anticancer (Renal cell carcinoma, advanced breast cancer, relapsed multiple myeloma and urothelial cancer)Herb-derived compoundsAlantolactone (Inula helenium L.)\[[@CIT0009]\]Antitumor (Liver cancer cells model)*Astragali Radix* (water extract)\[[@CIT0071]\]Apoptotic inductionCalphostin C (Cladosporium cladosporoides)\[[@CIT0072]\]Antitumor (Leukemia model), apoptotic inductionCAT (3,6,7-trimethoxyphenan-throindolizidine (isolated from *Tylophora atrofolliculata*))\[[@CIT0073]\]AntitumorDimethoxycurcumin (Curcumin analog)\[[@CIT0074]\]Antiproliferation and apoptosis induction (Human colon (HCT116) cancer cells model)Fisetin (flavonoid compound)\[[@CIT0075]\]Antiproliferation (Human leukemia (HL60), breast (MCF7), colon (HT29), liver (SK-HEP-1, Caco-2), neuroblastoma (SHEP, WAC-2), prostate (LNCaP, PC3) cells models)Flavone-8-acetic acid (FAA)\[[@CIT0076]\]Antitumor (Solid murine and human tumor cells models)Furanodiene (Rhizoma Curcumae)\[[@CIT0077]\]Antiproliferation (Human cervical (Hela), laryngeal (Hep-2), Leukemia (HL-60), prostate (PC3), and gastric (SGC-7901) cancer and fibrosarcoma (HT-1080) cells models)(-)-grandisin (extracted from *Piper solmsianum*)\[[@CIT0002],[@CIT0097]\]Antitumor (Ehrlich Ascites Tumoral (EAT) models)Irisflorentin (Belamcanda chinensis)\[[@CIT0078]\]Antiproliferation (prostate (DU145) and breast (MCF-7) cancer models)Leelamine (bark of pine tree)\[[@CIT0007]\]Antiproliferation by apoptotic induction (breast cancer model),MPD (Methyl protodioscin: isolated from *Dioscorea collettii* var. hypoglauca))\[[@CIT0079]\]Antiproliferation (Leukemia and solid tumors models)Oridonin (ORI) (Diterpinoid of *Isodon rubescens*)\[[@CIT0080]\]Antiproliferation (Murine and human melanoma cells models)Quercetin (flavonoid)\[[@CIT0098]\]Antiproliferative by apoptotic induction (Colon carcinoma (CT-26), prostate adenocarcinoma (LNCaP), lymphoblastic leukemia MOLT-4 T-cells, and human lymphoid (Raji) cell models), Antitumor (breast (MCF-7) and colon carcinoma (CT-26) models)Trabectedin (ET-743: isolated compound from *Ecteinascidia turbinata*)\[[@CIT0082]\]Anticancer (Soft tissue sarcoma, ovarian and breast cancer)Yuanhuapine (Isolated from *Daphne genkwa*)\[[@CIT0003]\]Antiproliferative (Murine lymphocytic leukemia (P-338), Human lung carcinoma (A-549) cells models)Ziyuglycoside II (*Sanguisorba officinalis* L.)\[[@CIT0083]\]Antiproliferative (Gastric and breast carcinoma) Figure 1Flow diagram summarizing steps for exclusion and inclusion of the research articles included in the analysis.

Out of 78 articles included in the analysis (42 in vitro, 42 in vivo, and 16 clinical studies), 47 (60.3%), 14 (17.9%) and 17 (21.8%) articles respectively, investigated metabolite profiles of conventional anticancer drugs/synthetic anticancer candidates, small-molecules targeted therapy, and herb-derived compounds with anticancer activities. These studies involved a total of 57 (57.0%) conventional anticancer drugs/synthetic anticancer candidates,[@CIT0006],[@CIT0013]--[@CIT0058] 22 (22.0%) studies for small-molecules targeted therapy,[@CIT0004],[@CIT0005],[@CIT0059]--[@CIT0070] and 21 (21.0%) studies for herb-derived compounds with anticancer activities[@CIT0002],[@CIT0003],[@CIT0007],[@CIT0009],[@CIT0071]--[@CIT0083] ([Tables 1](#T0001){ref-type="table"}--[3](#T0003){ref-type="table"}). Anticancer drugs or candidate compounds are metabolized by either Phase I, or phase II metabolizing enzyme alone, or both phase I and phase II metabolizing enzymes. The major metabolic pathways of phase I reaction include oxidation/hydroxylation and hydrolysis. The major metabolic pathways of phase II reaction are glucuronidation, methylation, and sulfation ([Tables 1](#T0001){ref-type="table"}--[3](#T0003){ref-type="table"}).

Several factors were found to influence the metabolite profiles of these drugs/compounds, including species, gender, and route and dose of administration. Relationship between the generated metabolites and anticancer activity and/or toxicity were reported in 10 (17.5%) studies for conventional anticancer drugs/synthetic anticancer candidates,[@CIT0006],[@CIT0013],[@CIT0022],[@CIT0031],[@CIT0032],[@CIT0036],[@CIT0045],[@CIT0050] 1 (4.5%) studies for small-molecules targeted therapy,[@CIT0065] and 4 (19.0%) studies for herb-derived compounds with anticancer activities.[@CIT0075],[@CIT0076],[@CIT0078],[@CIT0079]

Discussion {#S0004}
==========

The goals of conducting drug metabolism studies are to identify and characterize all major metabolites of the investigated drugs and specific enzymes responsible for their metabolism; to evaluate the impacts of the metabolites on safety and efficacy of the drug, and to utilize the drug metabolism information to maximize their intellectual property. The identity of metabolites present in any matrix of animal or human provides essential information about the biotransformation pathways involved in the clearance of a drug. Technological advances during the past decade have greatly improved analytical capabilities to detect, identify, and characterize metabolites at previously unattainable levels. Chromatography and electrophoresis are usually methods of choice. Electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) liquid chromatography-mass spectrometry (LC/MS) have become ideal and widely used methods in the identification, structure characterization, and quantitative analysis of drug metabolites. This is due to its superior specificity, sensitivity, and efficiency over other methods such as radioimmunoassay (RIA), gas chromatography/mass spectrometry (GC/MS),[@CIT0044] and liquid chromatography (LC) with ultraviolet detection (UV),[@CIT0019],[@CIT0076] fluorescence,[@CIT0034],[@CIT0045] radioactivity[@CIT0038],[@CIT0081] and mass spectrometry (MS)[@CIT0013],[@CIT0018],[@CIT0064] detection. Most of the works in metabolite analysis were carried out using triple-quadrupole mass spectrometers.[@CIT0028],[@CIT0039],[@CIT0055],[@CIT0057],[@CIT0063],[@CIT0082] The main advantages include its superior quantitative capabilities in the multiple reaction monitoring (MRM) mode and the fact that a family of metabolites can easily be identified using neutral-loss and precursor ion scans.

Factors Influencing Metabolite Formation {#S0004-S2001}
----------------------------------------

Several factors were shown to influence metabolite formation of the parent drugs/compounds with anticancer activities. These included species, gender, and route and dose of administration of the parent drugs/compounds.

### Species {#S0004-S2001-S3001}

Metabolic pathways and metabolite profiles of anticancer drugs/candidate compounds varied with animal species investigated. This is explained by the difference in the expression of metabolizing enzymes. For example, CYP1A1 and 1A2 enzymes are presented in mouse, rat, dog, monkey, and human, whereas CYP2C9, 2C19, 2D6, and 3A4 enzymes are only presented in human.[@CIT0099] In a study of flutamide (nonsteroidal antiandrogen used primarily for prostate cancer) metabolism, only one metabolite (designated OH-flu) was detected in human after incubation with human liver microsomes. On the other hand, four metabolites (Flu-1, OH-flu, M1, and M3) were detected after incubation of the compound with liver microsomes from rat, dog, and pig.[@CIT0032] Moreover, similar metabolite (OH-flu) was detected in rat and pig, but this metabolite was detected as 3 and 2 isoforms in rat and pig, respectively.[@CIT0032] For the synthetic β-lapachone, ARQ 501, similar phase I metabolites (M1-M3, and M5) were detected after incubation with whole blood of mouse, rat, dog, monkey, and human. On the other hand, only one phase I metabolite M4 was detected in human and M6 metabolite was detected in both human and monkey.[@CIT0014]

### Gender {#S0004-S2001-S3002}

Gender is another factor that influences the metabolite profiles of anticancer drugs/candidate compounds due to difference in the expression levels of metabolizing enzymes between males and females. For example, in human, the levels of CYP2E1 and 1A2 are found to be higher in males than females, while the level of CYP3A4 is higher in females.[@CIT0100] In rat liver, the expression level of CYP2C12 is higher in females than males, while the level of CYP2C11 is higher in males than females.[@CIT0101] Ventura et al investigated the metabolic profiles of irosustat (inhibitor of steroid sulfatase under development for hormone-sensitive cancers such as breast and prostate cancer) using liver microsomes from male and female rats, dogs, monkeys, and humans. In rats, 11 metabolites (designated M7-M11, M13-M16, M18 and 667-coumarin) were detected in both genders, while 1 different metabolite each was detected in males (P-24) and females (P-36).[@CIT0064] Eight similar metabolites (P-14, M7-M10, M13, M16, and P-24) were detected in both genders of monkeys, whereas only M14 metabolite was detected in only male monkeys. In dogs and humans, similar 14 metabolites were detected in both genders.[@CIT0064] These results suggest that the metabolites generated from the parent anticancer drugs/candidate compounds may vary depending on the expression levels of the responsible metabolizing enzymes in each gender.

### Route of Administration {#S0004-S2001-S3003}

Route of administration was found to be one contributing factor that influences the metabolite profiles of anticancer drugs/candidate compounds. Following intravenous administration of TW-01003 (a piperazinedione derivative designed as an antimitotic agent), the major metabolite (TW-01003 sulfate) was detected in rat plasma. Following oral administration, on the other hand, TW-01003 glucuronide became major metabolite.[@CIT0058] This might be due to the enterohepatic recirculation, which increases the level of glucuronide conjugates in the systemic circulation.[@CIT0058] In another metabolism study of tamoxifen (selective estrogen-receptor modulator for breast cancer), however, two similar metabolites (4-hydroxytamoxifen and *N*-desmethyltamoxifen) were detected in mouse serum following both oral and subcutaneous routes of administration.[@CIT0052]

### Dose {#S0004-S2001-S3004}

The dose level of anticancer drugs/candidate compounds was not found to be the major factor that influenced their metabolite profiles, but the metabolite levels. In the study of tamoxifen metabolism in mice, higher levels of metabolites were reported after an oral dose of 200 compared with 50 mg/kg/day.[@CIT0052] In the study of JM 216 or satraplatin, a platinum drug, the number of metabolites detected was similar among patients receiving different doses of the compound (120, 200, 300, 420, and 540 mg/m^2^). Plasma levels of each metabolite were not significantly different in patients who received different doses of the drug. For example, metabolite A was detected at 20--58.9% for 120 mg/m^2^, 10.2--50% for 200 mg/m^2^, 8.7--76.2% for 300 mg/m^2^, 8.2--85.9% for 420 mg/m^2^, and 5.1--44.4% for 540 mg/m2.[@CIT0036] Such broad range of metabolite levels in plasma observed in patients receiving the same dose might be due to inter-individual variability metabolizing enzyme(s) responsible for JM216 metabolism in each patient. These results suggest that the metabolite profiles of anticancer drugs/candidate compounds are not completely affected by the dose of administration but may be influenced by the dose level and duration of administration.

Contribution of Metabolites to Anticancer Activity and Toxicity of Anticancer Drugs/Candidate Compounds {#S0004-S2002}
-------------------------------------------------------------------------------------------------------

The metabolites generated from the parent anticancer drugs/candidate compounds can be both active and inactive metabolites. This information is essential for cancer chemotherapy with a narrow therapeutic window, particularly in individuals with increased or decreased drug-metabolizing enzyme activities influenced by genetic and nongenetic factors. Several studies showed that biotransformation could significantly influence the activity and toxicity of the anticancer drugs/candidate compounds. The metabolites of some active drugs/compounds exhibited more potent anticancer activity than their parent compounds. For example, the cytotoxic activity of the M3 metabolite of fisetin, a plant polyphenol, against Lewis carcinoma (LLC) cell line was shown to be about 2-fold of fisetin itself (IC~50~ or 50% inhibitory concentrations of 24 vs. 59 µM). However, both M3 and fisetin exhibited similar cytotoxic activities against the endothelial EAhy 926 cell line (IC~50~ 72 vs. 76 µM). It was noted however, that the cytotoxic activity of this metabolite against the normal cell line, NIH 3T3, was relatively higher than fisetin (IC~50~ 128 vs. 195 µM).[@CIT0075] The M1 and M2 metabolites of the synthetic compound irisflorentin were shown to exhibit more potent cytotoxic activity against human prostate cancer (DU145) and breast cancer (MCF-7) cell lines compared with the parent drug (IC~50~ 65.12 vs. 35.71 vs.\>300 µM and 74.17 vs. 36.30 vs.\>300 µM, respectively).[@CIT0078] The metabolite of a potent antileukemic compound, phyllanthoside, also exhibited lower cytotoxic activity against human rhabdomyosarcoma A204 cell line compared with the parent compound (IC~50~ of 24 µM and 0.47 nM, respectively).[@CIT0050] Some metabolites showed low or no cytotoxic activity. For example, The metabolite 6c of NSC 674495, an antitumor 2-(4-Aminophenyl) benzothiazoles, exhibited low cytotoxic activity against MCF-7 cell line (IC~50~\>100 M) and was not shown to be an active metabolite.[@CIT0045] The anticancer activities of the metabolites of these compounds should be further investigated in animals and humans to confirm their activities in vivo. Some metabolites may be pharmacologically inactive, while some may exhibit toxicity in animal models. For examples, 2-F-araH, the metabolite of 2-F-araA and the antitumor 9-β-D-arabinofuranosyl-2-fluoroadenine exhibited no antitumor activity in BDF~1~ mice bearing L1210 leukemia cells following 200 mg/kg intraperitoneal dosing for nine days.[@CIT0031] The M1 to M5 metabolites of JNJ-38877605 (a potent and selective Met receptor tyrosine kinase inhibitor) were shown to be associated with crystal formation in the kidney. The M10 metabolite, on the other hand, was shown to be the toxic metabolite found in humans (at sub-therapeutic dose 60 mg OD) and rats and was also noted as a species-specific toxic metabolite.[@CIT0065] Since renal toxicity could be observed even at a subtherapeutic dose, this toxicity is also likely to be observed at standard dose. The M14 metabolite of the tirapazamine analog SN30000 was found to be the cause of acute toxicity (hypothermia) similarly to the parent drug after the administration at the maximum tolerated dose (MTD: 186 mg/kg SN30000).[@CIT0006] However, hypothermia was also observed at 50% of MTD. Thus, this toxicity can be observed at the therapeutic dosage (75% of MTD).[@CIT0094]

Conclusion {#S0005}
==========

Drug metabolism plays a critical role in determining the pharmacological and toxicological effects of a drug in human. Metabolite profiling study is essential in determining therapeutic efficacy and toxicity of anticancer drugs/compounds from both chemical synthesis or natural sources. The generated metabolite profiles, either the types and amounts can be significantly influenced by factors such as species, gender, and route and dose of administration. Moreover, the metabolites can be both active and toxic metabolites, and some metabolites are inactive. The information of metabolite profile wills provides beneficial knowledge in anticancer agent development to improve anticancer activity and safety profiles of anticancer drugs or drug candidates.

The authors would like to thank the Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma (Thammasat University), Chulabhorn International College of Medicine (Thammasat University), and Drug Discovery and Development Center (Thammasat University) for providing all the necessary support in conducting this systematic review.

Author Contributions {#S0006}
====================

Nadda Muhamad: Conception and design, data analysis and interpretation, drafting the article, final approval, agreement to be accountable for the accuracy or integrity of the work.

Kesara Na-Bangchang: Conception and design, data analysis and interpretation, revising the article, final approval, agreement to be accountable for the accuracy or integrity of the work.

Disclosure {#S0007}
==========

The authors report no conflicts of interest in this work.

[^1]: **Abbreviations:** AMS, Accelerator Mass Spectrometry; ARC, Accurate Radioisotope Counting; DLM, Dog Liver Microsome; ESI, Electrospray Ionization; GC, Gas Chromatography; HLM, Human Liver Microsome; HPLC, High Performance Liquid Chromatography; IR, Infrared spectroscopy; IP, Intraperitoneal; IT, Ion trap; IV, Intravenous; LC, Liquid Chromatography; MLM, Monkey Liver Microsome; MS, Mass Spectrometry; NMR, Nuclear Magnetic Resonance spectroscopy; PLM, Pig Liver Microsome; PO, Per oral; QqQ, Triple quadrupole; QTOF, Quadrupole Time-of-flight; RD, Radio Detection; RLM, Rat Liver Microsome; SC, Subcutaneous; TIS, Turbo Ion Spray; UHPLC, Ultra-High Performance Liquid Chromatography; UPLC, Ultra Performance Liquid Chromatography; UV, Ultraviolet detection.

[^2]: **Abbreviations:** CYP, Cytochrome P450; DAD, Diode Array Detection; DLM, Dog Liver Microsome; ESI, Electrospray Ionization; HLM, Human Liver Microsome; HPLC, High Performance Liquid Chromatography; IT, Ion trap; IV, Intravenous; LC, Liquid Chromatography; LTQ, Linear Trap Quadrupole; MS, Mass Spectrometry; MLM, Monkey Liver Microsome; NMR, Nuclear Magnetic Resonance spectroscopy; PO, Per oral; QqQ, Triple quadrupole; QTOF, Quadrupole Time-of-flight; RLM, Rat Liver Microsome; TOF, Time-of-Flight; UHPLC, Ultra-high performance liquid chromatography; UPLC, Ultra Performance Liquid Chromatography; UV, Ultraviolet detection.

[^3]: **Abbreviations:** ESI, Electrospray Ionization; GC, Gas Chromatography; HLM, Human Liver Microsome; HPLC, High Performance Liquid Chromatography; HR, High Resonance; HRSI, High Resolution Single Ion; IP, Intraperitoneal; IV, Intravenous; LC, Liquid Chromatography; MS, Mass Spectrometry; MLM, Monkey Liver Microsome; NMR, Nuclear Magnetic Resonance spectroscopy; PO, Per oral; QqQ, Triple quadrupole; LIT, Linear Ion Trap; LSC, Liquid Scintillation Counting; QTOF, Quadrupole Time-of-flight; QTRAP, Linear ion trap Triple Quadrupole; RD, Radio Detection; RLM, Rat Liver Microsome; RRLC, Rapid Resonance Liquid Chromatography; TIS, Turbo Ion Spray; TOF, Time-of-Flight; UHPLC, Ultra-high performance liquid chromatography; UPLC, Ultra Performance Liquid Chromatography; UV, Ultraviolet detection.
